161 related articles for article (PubMed ID: 16877525)
1. Tumor-specific expression of the RGD-alpha3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice.
Miyoshi T; Hirohata S; Ogawa H; Doi M; Obika M; Yonezawa T; Sado Y; Kusachi S; Kyo S; Kondo S; Shiratori Y; Hudson BG; Ninomiya Y
FASEB J; 2006 Sep; 20(11):1904-6. PubMed ID: 16877525
[TBL] [Abstract][Full Text] [Related]
2. Distinct antitumor properties of a type IV collagen domain derived from basement membrane.
Maeshima Y; Colorado PC; Torre A; Holthaus KA; Grunkemeyer JA; Ericksen MB; Hopfer H; Xiao Y; Stillman IE; Kalluri R
J Biol Chem; 2000 Jul; 275(28):21340-8. PubMed ID: 10766752
[TBL] [Abstract][Full Text] [Related]
3. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
Boosani CS; Mannam AP; Cosgrove D; Silva R; Hodivala-Dilke KM; Keshamouni VG; Sudhakar A
Blood; 2007 Aug; 110(4):1168-77. PubMed ID: 17426256
[TBL] [Abstract][Full Text] [Related]
4. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth.
Hamano Y; Kalluri R
Biochem Biophys Res Commun; 2005 Jul; 333(2):292-8. PubMed ID: 15979458
[TBL] [Abstract][Full Text] [Related]
5. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
[TBL] [Abstract][Full Text] [Related]
6. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion.
Pedchenko V; Zent R; Hudson BG
J Biol Chem; 2004 Jan; 279(4):2772-80. PubMed ID: 14610079
[TBL] [Abstract][Full Text] [Related]
7. Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain.
Leinonen A; Netzer KO; Boutaud A; Gunwar S; Hudson BG
Kidney Int; 1999 Mar; 55(3):926-35. PubMed ID: 10027929
[TBL] [Abstract][Full Text] [Related]
8. Tetrastatin, the NC1 domain of the α4(IV) collagen chain: a novel potent anti-tumor matrikine.
Brassart-Pasco S; Sénéchal K; Thevenard J; Ramont L; Devy J; Di Stefano L; Dupont-Deshorgue A; Brézillon S; Feru J; Jazeron JF; Diebold MD; Ricard-Blum S; Maquart FX; Monboisse JC
PLoS One; 2012; 7(4):e29587. PubMed ID: 22539938
[TBL] [Abstract][Full Text] [Related]
9. The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent.
Floquet N; Pasco S; Ramont L; Derreumaux P; Laronze JY; Nuzillard JM; Maquart FX; Alix AJ; Monboisse JC
J Biol Chem; 2004 Jan; 279(3):2091-100. PubMed ID: 14583633
[TBL] [Abstract][Full Text] [Related]
10. Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells.
Pallini R; Pierconti F; Falchetti ML; D'Arcangelo D; Fernandez E; Maira G; D'Ambrosio E; Larocca LM
J Neurosurg; 2001 Jun; 94(6):961-71. PubMed ID: 11409526
[TBL] [Abstract][Full Text] [Related]
11. [Reconstruction of adenovirus vector contained canstatin gene and hTERT gene core promoter and its anti-tumor effect in human ovarian cancer].
Zhu BJ; Qiao YH; Li Y
Zhonghua Fu Chan Ke Za Zhi; 2009 Mar; 44(3):214-8. PubMed ID: 19570449
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
13. Selective binding of integrins from different renal cell types to the NC1 domain of alpha3 and alpha1 chains of type IV collagen.
Aggeli AS; Kitsiou PV; Tzinia AK; Boutaud A; Hudson BG; Tsilibary EC
J Nephrol; 2009; 22(1):130-6. PubMed ID: 19229828
[TBL] [Abstract][Full Text] [Related]
14. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
15. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties.
Maeshima Y; Colorado PC; Kalluri R
J Biol Chem; 2000 Aug; 275(31):23745-50. PubMed ID: 10837460
[TBL] [Abstract][Full Text] [Related]
16. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
He GA; Luo JX; Zhang TY; Hu ZS; Wang FY
Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609
[TBL] [Abstract][Full Text] [Related]
17. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras.
MacKenzie KL; Franco S; Naiyer AJ; May C; Sadelain M; Rafii S; Moore MA
Oncogene; 2002 Jun; 21(27):4200-11. PubMed ID: 12082607
[TBL] [Abstract][Full Text] [Related]
18. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter].
Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B
Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959
[TBL] [Abstract][Full Text] [Related]
19. Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo.
Roth JM; Akalu A; Zelmanovich A; Policarpio D; Ng B; MacDonald S; Formenti S; Liebes L; Brooks PC
Am J Pathol; 2005 Mar; 166(3):901-11. PubMed ID: 15743801
[TBL] [Abstract][Full Text] [Related]
20. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells.
Murasawa S; Llevadot J; Silver M; Isner JM; Losordo DW; Asahara T
Circulation; 2002 Aug; 106(9):1133-9. PubMed ID: 12196341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
